Early Hepatocellular Carcinoma: Diagnosing the Difficult Nodule


The incidence of hepatocellular carcinoma (HCC) is rising worldwide. Although the best chance for long-term survival is early detection, screening high-risk populations to detect HCC when it is most treatable still has only limited success. Once detected within the cirrhotic liver, many observations still defy correct characterization, due in part to a history of nonstandarized nomenclature and reporting patterns. Recently, however, an initiative by the American College of Radiology, Liver Imaging-Reporting and Data System (LI-RADS), has begun to remedy these inadequacies. Here, we review LI-RADS, and focus in particular on the difficult nodule, i.e., a radiological observation that challenges our current diagnostic ability, and review essential technical imaging features that aid in the diagnosis of early HCC.

Share and Cite:

S. Farooqui, N. Ravendhran and S. Cunningham, "Early Hepatocellular Carcinoma: Diagnosing the Difficult Nodule," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 651-661. doi: 10.4236/jct.2013.42081.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] H. B. El-Serag, “Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma,” Gastroenterology, Vol. 142, No. 6, 2012, pp. 1264-1273.
[2] D. M. Parkin, F. Bray, J. Ferlay, et al., “Global Cancer Statistics, 2002,” CA Cancer Journal for Clinicians, Vol. 55, No. 2, 2005, pp. 74-108. doi:10.3322/canjclin.55.2.74
[3] J. M. Llovet, A. Burroughs and J. Bruix, “Hepatocellular Carcinoma,” Lancet, Vol. 362, No. 9399, 2003, pp. 1907-1917. doi:10.1016/S0140-6736(03)14964-1
[4] American Cancer Society, “Cancer Facts and Figures 2012,” 2012. http://www.cancer.org/acs/ groups/content/@epidemiologysu rveilance/documents/docume nt/acspc-031941.pdf
[5] B. Q. Starley, C. J. Calcagno and S. A. Harrison, “NonAlcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection,” Hepatology, Vol. 51, No. 5, 2010, pp. 1820-1832. doi:10.1002/hep.23594
[6] H. B. El-Serag, H. Hampel and F. Javadi, “The Association between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence,” Clinical Gastroenterology and Hepatology, Vol. 4, No. 3, 2006, pp. 369-380. doi:10.1016/j.cgh.2005.12.007
[7] B. H. Zhang, B. H. Yang and Z. Y. Tang, “Randomized Controlled Trial of Screening for Hepatocellular Carcinoma,” Journal of Cancer Research and Clinical Oncology, Vol. 130, No. 7, 2004, pp. 417-422. doi:10.1007/s00432-004-0552-0
[8] R. Aghoram, P. Cai and J. A. Dickinson, “Alpha-Foetoprotein and/or Liver Ultrasonography for Screening of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B,” Cochrane Database Systematic Reviews, Vol. 9, 2012, Article ID: CD002799. doi:10.1002/14651858.CD002799.pub2
[9] J. C. Trinchet, C. Chaffaut, V. Bourcier, et al., “Ultrasonographic Surveillance of Hepatocellular Carcinoma in Cirrhosis: A Randomized Trial Comparing 3-and 6-Month Periodicities,” Hepatology, Vol. 54, No. 6, 2011, pp. 1987-1997. doi:10.1002/hep.24545
[10] L. Bolondi, S. Sofia, S. Siringo, et al., “Surveillance Programme of Cirrhotic Patients for Early Diagnosis and Treatment of Hepatocellular Carcinoma: A Cost Effectiveness Analysis,” Gut, Vol. 48, No. 2, 2001, pp. 251-259. doi:10.1136/gut.48.2.251
[11] G. Bertino, A. Ardiri, M. Malaguarnera, et al., “Hepatocellualar Carcinoma Serum Markers,” Seminars in Oncology, Vol. 39, No. 4, 2012, pp. 410-433. doi:10.1053/j.seminoncol.2012.05.001
[12] R. Masuzaki, S. J. Karp and M. Omata, “New Serum Markers of Hepatocellular Carcinoma,” Seminars in Oncology, Vol. 39, No. 4, 2012, pp. 434-439. doi:10.1053/j.seminoncol.2012.05.009
[13] A. S. Purysko, E. M. Remer, C. P. Coppa, et al., “LIRADS: A Case-Based Review of the New Categorization of Liver Findings in Patients with End-Stage Liver Disease,” Radiographics, Vol. 32, No. 7, 2012, pp. 1977-1995. doi:10.1148/rg.327125026
[14] LI-RADS, “Liver Imaging-Reporting and Data System,” 2013. http://www.acr.org/Quality-Safety/Reso urces/LIRADS
[15] D. J. Becker-Weidman, B. Kalb, P. Sharma, et al., “Hepatocellular Carcinoma Lesion Characterization: Single-Institution Clinical Performance Review of Multiphase Gadolinium-Enhanced MR Imaging—Comparison to Prior Same-Center Results after MR Systems Improvements,” Radiology, Vol. 261, No. 3, 2011, pp. 824-833. doi:10.1148/radiol.11110157
[16] P. Sharma, B. Kalb, H. D. Kitajima, et al., “Optimization of Single Injection Liver Arterial Phase Gadolinium Enhanced MRI Using Bolus Track Real-Time Imaging,” Journal of Magnetic Resonance Imaging, Vol. 33, No. 1, 2011, pp. 110-118. doi:10.1002/jmri.22200
[17] S. C. Cunningham and S. Farooqui, “Subspecialty Radiology and Surgery,” Hepatobiliary & Pancreatic Diseases International, Vol. 12, No. 2, 2013, pp. 122-124.
[18] S. F. Altekruse, K. A. McGlynn, L. A. Dickie, et al., “Hepatocellular Carcinoma Confirmation, Treatment, and Survival in Surveillance, Epidemiology, and End Results Registries, 1992-2008,” Hepatology, Vol. 55, No. 2, 2012, pp. 476-482. doi:10.1002/hep.24710
[19] National Comprehensive Cancer Network, “NCCN Clinical Practice Guidelines in Oncology,” 2013. http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
[20] D. N. Hoffer, A. Finelli, R. Chow, et al., “Structured Electronic Operative Reporting: Comparison with Dictation in Kidney Cancer Surgery,” International Journal of Medical Informatics, Vol. 81, No. 3, 2012, pp. 182-191. doi:10.1016/j.ijmedinf.2011.11.008
[21] D. A. Cowan, M. B. Sands, S. M. Rabizadeh, et al., “Electronic Templates versus Dictation for the Completion of Mohs Micrographic Surgery Operative Notes,” Dermatologic Surgery, Vol. 33, No. 5, 2007, pp. 588-595. doi:10.1111/j.1524-4725.2007.33120.x
[22] L. A. Mack, K. Dabbs and W. J. Temple, “Synoptic Operative Record for Point of Care Outcomes: A Leap Forward in Knowledge Translation,” European Journal of Surgical Oncology, Vol. 36, Suppl. 1, 2010, pp. S44-49.
[23] J. M. Lee, F. Trevisani, V. Vilgrain, et al., “Imaging Diagnosis and Staging of Hepatocellular Carcinoma,” Liver Transplantation, Vol. 17, Suppl. 2, 2011, pp. S34-43.
[24] International Working Party, “Terminology of Nodular Hepatocellular Lesions,” Hepatology, Vol. 22, No. 3, 1995, pp. 983-993.
[25] R. F. Hanna, D. A. Aguirre, N. Kased, et al., “CirrhosisAssociated Hepatocellular Nodules: Correlation of Histopathologic and MR Imaging Features1,” Radiographics, Vol. 28, No. 3, 2008, pp. 747-769. doi:10.1148/rg.283055108
[26] G. Brancatelli, M. P. Federle, L. Grazioli, et al., “Large Regenerative Nodules in Budd-Chiari Syndrome and Other Vascular Disorders of the Liver,” American Journal of Roentgenology, Vol. 178, No. 4, 2002, pp. 877-883. doi:10.2214/ajr.178.4.1780877
[27] A. Qayyum, A. Graser, A. Westphalen, et al., “CT of Benign Hypervascular Liver Nodules in Autoimmune Hepatitis,” American Journal of Roentgenology, Vol. 183, No. 6, 2004, pp. 1573-1576. doi:10.2214/ajr.183.6.01831573
[28] G. A. Krinsky, V. S. Lee, M. T. Nguyen, et al., “Siderotic Nodules at MR Imaging: Regenerative or Dysplastic?” Journal of Computer Assisted Tomography, Vol. 24, No. 5, 2000, pp. 773-776.
[29] G. A. Krinsky, V. S. Lee, N. D. Theise, et al., “Hepatocellular Carcinoma and Dysplastic Nodules in Patients with Cirrhosis: Prospective Diagnosis with MR Imaging and Explantation Correlation1,” Radiology, Vol. 219, No. 2, 2001, pp. 445-454.
[30] N. D. Theise, M. Schwartz, C. Miller, et al., “Macroregenerative Nodules and Hepatocellular Carcinoma in FortyFour Sequential Adult Liver Explants with Cirrhosis,” Hepatology, Vol. 16, No. 4, 1992, pp. 949-955. doi:10.1002/hep.1840160416
[31] S. Efremidis and P. Hytiroglou, “The Multistep Process of Hepatocarcinogenesis in Cirrhosis with Imaging Correlation,” European Radiology, Vol. 12, No. 4, 2002, pp. 753-764. doi:10.1007/s00330-001-1142-z
[32] M. Borzio, S. Fargion, F. Borzio, et al., “Impact of Large Regenerative, Low Grade and High Grade Dysplastic Nodules in Hepatocellular Carcinoma Development,” Journal of Hepatology, Vol. 39, No. 2, 2003, pp. 208-214. doi:10.1016/S0168-8278(03)00190-9
[33] J. M. Willatt, H. K. Hussain, S. Adusumilli, et al., “MR Imaging of Hepatocellular Carcinoma in the Cirrhotic Liver: Challenges and Controversies1,” Radiology, Vol. 247, No. 2, 2008, pp. 311-330. doi:10.1148/radiol.2472061331
[34] M. Hayashi, O. Matsui, K. Ueda, et al., “Correlation between the Blood Supply and Grade of Malignancy of Hepatocellular Nodules Associated with Liver Cirrhosis: Evaluation by CT during Intraarterial Injection of Contrast Medium,” American Journal of Roentgenology, Vol. 172, No. 4, 1999, pp. 969-976. doi:10.2214/ajr.172.4.10587130
[35] J. Bruix and M. Sherman, “Management of Hepatocellular Carcinoma: An Update,” Hepatology, Vol. 53, No. 3, 2011, pp. 1020-1022. doi:10.1002/hep.24199
[36] L. Di Tommaso, G. Franchi, Y. N. Park, et al., “Diagnostic Value of HSP70, Glypican 3, and Glutamine Synthetase in Hepatocellular Nodules in Cirrhosis,” Hepatology, Vol. 45, No. 3, 2007, pp. 725-734. doi:10.1002/hep.21531
[37] International Consensus Group for Hepatocellular Neoplasia, “Pathologic Diagnosis of Early Hepatocellular Carcinoma: A Report of the International Consensus Group for Hepatocellular Neoplasia,” Hepatology, Vol. 49, No. 2, 2009, pp. 658-664. doi:10.1002/hep.22709
[38] M. Roncalli, M. Borzio and L. Di Tommaso, “Hepatocellular Dysplastic Nodules,” Hepatology Research, Vol. 37, Suppl. S2, 2007, pp. S125-S134.
[39] M. Kojiro and T. Roskams, “Early Hepatocellular Carcinoma and Dysplastic Nodules,” Seminars in Liver Disease, Vol. 25, No. 2, 2005, pp. 133-142.
[40] O. Matsui, M. Kadoya, T. Kameyama, et al., “Benign and Malignant Nodules in Cirrhotic Livers: Distinction Based on Blood Supply,” Radiology, Vol. 178, No. 2, 1991, pp. 493-497.
[41] A. E. Holland, E. M. Hecht, W. Y. Hahn, et al., “Importance of Small (< or = 20-mm) Enhancing Lesions Seen Only during the Hepatic Arterial Phase at MR Imaging of the Cirrhotic Liver: Evaluation and Comparison with Whole Explanted Liver,” Radiology, Vol. 237, No. 3, 2005, pp. 938-944. doi:10.1148/radiol.2373041364
[42] J. A. Marrero, H. K. Hussain, H. V. Nghiem, et al., “Improving the Prediction of Hepatocellular Carcinoma in Cirrhotic Patients with an Arterially-Enhancing Liver Mass,” Liver Transplantation, Vol. 11, No. 3, 2005, pp. 281-289. doi:10.1002/lt.20357
[43] J. S. Yu, K. W. Kim, K. B. Sung, et al., “Small Arterial-Portal Venous Shunts: A Cause of Pseudolesions at Hepatic Imaging,” Radiology, Vol. 203, No. 3, 1997, pp. 737-742.
[44] J.-S. Yu, K. W. Kim, M.-G. Jeong, et al., “Nontumorous Hepatic Arterial-Portal Venous Shunts: MR Imaging Findings1,” Radiology, Vol. 217, No. 3, 2000, pp. 750-756.
[45] G. D. Dodd, R. L. Baron, J. H. Oliver, et al., “Spectrum of Imaging Findings of the Liver in End-Stage Cirrhosis: Part I, Gross Morphology and Diffuse Abnormalities,” American Journal of Roentgenology, Vol. 173, No. 4, 1999, pp. 1031-1036. doi:10.2214/ajr.173.4.10511173
[46] A. Colli, M. Fraquelli, G. Casazza, et al., “Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review,” The American Journal of Gastroenterol, Vol. 101, No. 3, 2006, pp. 513-523. doi:10.1111/j.1572-0241.2006.00467.x
[47] V. de Ledinghen, D. Laharie, R. Lecesne, et al., “Detection of Nodules in Liver Cirrhosis: Spiral Computed Tomography or Magnetic Resonance Imaging? A Prospective Study of 88 Nodules in 34 Patients,” European Journal of Gastroenterology & Hepatology, Vol. 14, No. 2, 2002, pp. 159-165. doi:10.1097/00042737-200202000-00010
[48] A. Rode, B. Bancel, P. Douek, et al., “Small Nodule Detection in Cirrhotic Livers: Evaluation with US, Spiral CT, and MRI and Correlation with Pathologic Examination of Explanted Liver,” Journal of Computer Assisted Tomography, Vol. 25, No. 3, 2001, pp. 327-336. doi:10.1097/00004728-200105000-00001
[49] G. L. Bennett, G. A. Krinsky, R. J. Abitbol, et al., “Sonographic Detection of Hepatocellular Carcinoma and Dysplastic Nodules in Cirrhosis: Correlation of Pretransplantation Sonography and Liver Explant Pathology in 200 Patients,” AJR American Journal of Roentgenology, Vol. 179, No. 1, 2002, pp. 75-80. doi:10.2214/ajr.179.1.1790075
[50] A. Shimizu, K. Ito, S. Koike, et al., “Cirrhosis or Chronic Hepatitis: Evaluation of Small (< or =2-cm) Early-Enhancing Hepatic Lesions with Serial Contrast-Enhanced Dynamic MR Imaging,” Radiology, Vol. 226, No. 2, 2003, pp. 550-555. doi:10.1148/radiol.2262011967
[51] Y. Y. Jeong, D. G. Mitchell and T. Kamishima, “Small (<20 mm) Enhancing Hepatic Nodules Seen on Arterial Phase MR Imaging of the Cirrhotic Liver: Clinical Implications,” AJR American Journal of Roentgenology, Vol. 178, No. 6, 2002, pp. 1327-1334. doi:10.2214/ajr.178.6.1781327
[52] P. Hytiroglou and N. Theise, “Differential Diagnosis of Hepatocellular Nodular Lesions,” Seminars in Diagnostic Pathology, Vol. 15, No. 4, 1998, pp. 285-299.
[53] L. Bolondi, S. Gaiani, N. Celli, et al., “Characterization of Small Nodules in Cirrhosis by Assessment of Vascularity: The Problem of Hypovascular Hepatocellular Carcinoma,” Hepatology, Vol. 42, No. 1, 2005, pp. 27-34. doi:10.1002/hep.20728
[54] T. C. Lauenstein, K. Salman, R. Morreira, et al., “Gadolinium-Enhanced MRI for Tumor Surveillance Before Liver Transplantation: Center-Based Experience,” American Journal of Roentgenology, Vol. 189, No. 3, 2007, pp. 663-670. doi:10.2214/AJR.07.2171
[55] C. J. R. Stewart, J. Coldewey and I. S. Stewart, “Comparison of Fine Needle Aspiration Cytology and Needle Core Biopsy in the Diagnosis of Radiologically Detected Abdominal Lesions,” Journal of Clinical Pathology, Vol. 55, No. 2, 2002, pp. 93-97. doi:10.1136/jcp.55.2.93
[56] F. O. Durand, J. M. Regimbeau, J. Belghiti, et al., “Assessment of the Benefits and Risks of Percutaneous Biopsy before Surgical Resection of Hepatocellular Carcinoma,” Journal of Hepatology, Vol. 35, No. 2, 2001, pp. 254-258. doi:10.1016/S0168-8278(01)00108-8
[57] J. H. Lim, D. Choi, S. H. Kim, et al., “Detection of Hepatocellular Carcinoma: Value of Adding Delayed Phase Imaging to Dual-Phase Helical CT,” American Journal of Roentgenology, Vol. 179, No. 1, 2002, pp. 67-73. doi:10.2214/ajr.179.1.1790067
[58] R. C. Carlos, H. M. Kim, H. K. Hussain, et al., “Developing a Prediction Rule to Assess Hepatic Malignancy in Patients with Cirrhosis,” American Journal of Roentgenology, Vol. 180, No. 4, 2003, pp. 893-900. doi:10.2214/ajr.180.4.1800893
[59] R. Iannaccone, A. Laghi, C. Catalano, et al., “Hepatocellular Carcinoma: Role of Unenhanced and Delayed Phase Multi-Detector Row Helical CT in Patients with Cirrhosis,” Radiology, Vol. 234, No. 2, 2005, pp. 460-467. doi:10.1148/radiol.2342031202
[60] D. Choi, D. G. Mitchell, S. K. Verma, et al., “Hepatocellular Carcinoma with Indeterminate or False-Negative Findings at Initial MR Imaging: Effect on Eligibility for Curative Treatment: Initial Observations,” Radiology, Vol. 244, No. 3, 2007, pp. 776-783. doi:10.1148/radiol.2443061355
[61] J.-J. Chung, J. S. Yu, J. H. Kim, et al., “Nonhypervascular Hypoattenuating Nodules Depicted on Either Portal or Equilibrium Phase Multiphasic CT Images in the Cirrhotic Liver,” American Journal of Roentgenology, Vol. 191, No. 1, 2008, pp. 207-214. doi:10.2214/AJR.07.3409
[62] A. E. Holland, E. M. Hecht, W. Y. Hahn, et al., “Importance of Small (≤20-mm) Enhancing Lesions Seen Only during the Hepatic Arterial Phase at MR Imaging of the Cirrhotic Liver: Evaluation and Comparison with Whole Explanted Liver,” Radiology, Vol. 237, No. 3, 2005, pp. 938-944. doi:10.1148/radiol.2373041364
[63] S. H. Choi, J. M. Lee, N. C. Yu, et al., “Hepatocellular Carcinoma in Liver Transplantation Candidates: Detection with Gadobenate Dimeglumine-Enhanced MRI,” American Journal of Roentgenology, Vol. 191, No. 2, 2008, pp. 529-536. doi:10.2214/AJR.07.2565
[64] R. B. Freeman, A. Mithoefer, R. Ruthazer, et al., “Optimizing Staging for Hepatocellular Carcinoma before Liver Transplantation: A Retrospective Analysis of the UNOS/OPTN Database,” Liver Transplantation, Vol. 12, No. 10, 2006, pp. 1504-1511. doi:10.1002/lt.20847
[65] A. Forner, R. N. Vilana, C. Ayuso, et al., “Diagnosis of Hepatic Nodules 20 mm or Smaller in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma,” Hepatology, Vol. 47, No. 1, 2008, pp. 97-104. doi:10.1002/hep.21966
[66] B. Taouli, V. R. Vilgrain, E. Dumont, et al., “Evaluation of Liver Diffusion Isotropy and Characterization of Focal Hepatic Lesions with Two Single-Shot Echo-Planar MR Imaging Sequences: Prospective Study in 66 Patients,” Radiology, Vol. 226, No. 1, 2003, pp. 71-78. doi:10.1148/radiol.2261011904
[67] T. Parikh, S. J. Drew, V. S. Lee, et al., “Focal Liver Lesion Detection and Characterization with Diffusion-Weighted MR Imaging: Comparison with Standard Breath-Hold T2-Weighted Imaging,” Radiology, Vol. 246, No. 3, 2008, pp. 812-822. doi:10.1148/radiol.2463070432
[68] J. H. Lim, D. Choi, S. K. Cho, et al., “Conspicuity of Hepatocellular Nodular Lesions in Cirrhotic Livers at Ferumoxides-Enhanced MR Imaging: Importance of Kupffer Cell Number,” Radiology, Vol. 220, No. 3, 2001, pp. 669-676. doi:10.1148/radiol.2203001777
[69] K. I. Ringe, D. B. Husarik, C. B. Sirlin, et al., “Gadoxetate Disodium-Enhanced MRI of the Liver: Part 1, Protocol Optimization and Lesion Appearance in the Noncirrhotic Liver,” American Journal of Roentgenology, Vol. 195, No. 1, 2010, pp. 13-28. doi:10.2214/AJR.10.4392
[70] D. Marin, M. Di Martino, A. Guerrisi, et al., “Hepatocellular Carcinoma in Patients with Cirrhosis: Qualitative Comparison of Gadobenate Dimeglumine-Enhanced MR Imaging and Multiphasic 64-Section CT1,” Radiology, Vol. 251, No. 1, 2009, pp. 85-95. doi:10.1148/radiol.2511080400
[71] I. Cruite, M. Schroeder, E. M. Merkle, et al., “Gadoxetate Disodium-Enhanced MRI of the Liver: Part 2, Protocol Optimization and Lesion Appearance in the Cirrhotic Liver,” American Journal of Roentgenology, Vol. 195, No. 1, 2010, pp. 29-41. doi:10.2214/AJR.10.4538
[72] G. Brancatelli, R. L. Baron, M. S. Peterson, et al., “Helical CT Screening for Hepatocellular Carcinoma in Patients with Cirrhosis: Frequency and Causes of FalsePositive Interpretation,” American Journal of Roentgenology, Vol. 180, No. 4, 2003, pp. 1007-1014. doi:10.2214/ajr.180.4.1801007
[73] M. Kudo and T. Okanoue, “Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Manual Proposed by the Japan Society of Hepatology,” Oncology, Vol. 72, Suppl. 1, 2007, pp. 2-15.
[74] G. A. Krinsky and G. Israel, “Nondysplastic Nodules That Are Hyperintense on T1-Weighted Gradient-Echo MR Imaging: Frequency in Cirrhotic Patients Undergoing Transplantation,” American Journal of Roentgenology, Vol. 180, No. 4, 2003, pp. 1023-1027. doi:10.2214/ajr.180.4.1801023
[75] T. Kim, R. L. Baron and M. A. Nalesnik, “Infarcted Regenerative Nodules in Cirrhosis,” American Journal of Roentgenology, Vol. 175, No. 4, 2000, pp. 1121-1125. doi:10.2214/ajr.175.4.1751121
[76] B. Choi, J. Han, S. Hong, et al., “Dysplastic Nodules of the Liver: Imaging Findings,” Abdominal Imaging, Vol. 24, No. 3, 1999, pp. 250-257. doi:10.1007/s002619900490
[77] G. A. Krinsky, N. D. Theise, N. M. Rofsky, et al., “Dysplastic Nodules in Cirrhotic Liver: Arterial Phase Enhancement at CT and MR Imaging—A Case Report,” Radiology, Vol. 209, No. 2, 1998, pp. 461-464.
[78] N. L. Kelekis, R. C. Semelka, S. Worawattanakul, et al., “Hepatocellular Carcinoma in North America: A Multiinstitutional Study of Appearance on T1-Weighted, T2-Weighted, and Serial Gadolinium-Enhanced Gradient-Echo Images,” American Journal of Roentgenology, Vol. 170, No. 4, 1998, pp. 1005-1013. doi:10.2214/ajr.170.4.9530051
[79] J. P. Earls, N. D. Theise, J. C. Weinreb, et al., “Dysplastic Nodules and Hepatocellular Carcinoma: Thin-Section MR Imaging of Explanted Cirrhotic Livers with Pathologic Correlation,” Radiology, Vol. 201, No. 1, 1996, pp. 207-214.
[80] M. Sherman, “Diagnosis of Small Hepatocellular Carcinoma,” Hepatology, Vol. 42, No. 1, 2005, pp. 14-16. doi:10.1002/hep.20790

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.